Physician profile
David G Li
NPI 1891355186
$3,419.23
in general payments reported to CMS, 2019-2025
13 companies · $2,472 in 2025
The $2,472 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $246 · 2023: $249 · 2024: $452 · 2025: $2,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046 · Travel and Lodging: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.02 |
| Travel and Lodging | $1,127.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $1,532.07 | 2025 | Vtama |
| Abbvie INC. | $508.12 | 2023-2025 | |
| Ucb, INC. | $252.36 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $236.87 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $234.45 | 2022-2025 | Sotyktu |
| Incyte Corporation | $133.11 | 2024-2025 | Opzelura, Opzelura |
| Biofrontera INC. | $123.84 | 2022 | |
| Amgen INC. | $118.62 | 2025 | Otezla |
| Galderma Laboratories, L.P. | $87.25 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.15 | 2023 | |
| Leo Pharma INC. | $64.40 | 2023 | Adbry |
| Dermavant Sciences, INC. | $23.96 | 2023 | Vtama |
| Botanix Sb INC | $21.03 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.